Meningitis B Booster Shot Study for Young Adults
Part of Infections clinical trials.
This trial tests two different booster shots for meningitis B in young adults who already got the Bexsero vaccine at least 2.5 years ago. The goal is to see which booster works best to keep you protected.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You received two doses of the Bexsero meningitis B vaccine at least 2.5 years ago.
- You are in good general health based on a medical checkup.
- If you are a woman who could become pregnant, you must use birth control starting 28 days before the shot and continuing for 28 days after.
- You cannot have had any other meningitis B vaccine in the last 2.5 years.
- You cannot be pregnant or breastfeeding.
- You cannot have a serious health condition like a weak immune system, a bleeding disorder, or a history of seizures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests how safe and how well the immune system responds to three different meningococcal B vaccine approaches in people who do not have a spleen. It may help future adults like you choose a safer, more effective prevention strategy against meningococcal B infection.
This trial tests a new vaccine called DX-104 to see if it is safe and helps the body fight meningitis B. Healthy adults aged 18-50 can join to help find a better way to prevent this infection.
This study tests a meningococcal B vaccine in adults who have had their spleen removed or have a spleen that doesn't work well (asplenia). It will compare how well the vaccine works in these patients versus healthy adults to see if it provides good protection.
This trial tests a meningitis B vaccine (MenB-4C) in children and young adults with autoimmune rheumatic diseases. It aims to see if the vaccine is safe and works well for these patients.
This trial tests a new meningitis vaccine (GNG-DE) to see how well it works compared to a vaccine already on the market. It might help protect you or your child from meningococcal disease.
This trial tests a new vaccine that helps protect against 6 types of meningococcal bacteria, which can cause serious infections like meningitis. It is for healthy people aged 2 to 59 years.
Hear when a new Neisseria Meningitidis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.